Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    August 5, 2026

    Skye Africa Intelligence and ECSA-HC Sign Memorandum of Understanding to Scale AI-Enabled Health Solutions

    August 5, 2026

    Guatemala raises red alert as Fuego volcano erupts

    August 5, 2026
    Facebook X (Twitter) Instagram
    Mashreq DailyMashreq Daily
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Mashreq DailyMashreq Daily
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Risk-On or Risk-Off? How to Read Global Sentiment Before You Trade

    July 20, 2026

    Bond Yields Are Moving FX More Than Headlines – Here’s Why

    July 13, 2026

    Tamchy Special Financial Investment Territory on Issyk-Kul Launched in Kyrgyzstan

    July 6, 2026
    Latest News

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    Health August 5, 2026

    The study will operate at three Canadian sites and enroll about 80 healthy adults. Researchers will assess the vaccine’s safety, tolerability and ability to produce an immune response. The trial will not determine whether the vaccine prevents infection because Phase 1 studies focus on early safety data. The Coalition for Epidemic Preparedness Innovations has committed up to $50 million for preclinical work, the trial and production of additional research doses. WHO recorded 3,605 confirmed cases and 1,587 deaths in DR Congo through July 30. At least 651 patients had recovered by that date. Updated figures cited by CEPI on August 4 placed infections above 3,800 and deaths above 1,700. Cases had reached 49 health zones across Ituri, North Kivu, South Kivu, Haut-Uélé and Tshopo provinces. Thirty-three health zones had reported recent infections, while Ituri accounted for 88% of confirmed cases.

    Guatemala raises red alert as Fuego volcano erupts

    August 5, 2026

    OECD inflation eases to 4.2% as lower energy rates take hold

    August 5, 2026

    Oil prices fall as Brent and WTI reach three-week lows again

    August 5, 2026

    Eastern Washington fires leave 700 structures destroyed

    August 4, 2026

    Michigan reports first deaths tied to cyclospora outbreak

    August 4, 2026

    Oil prices swing after Brent tops $90 on supply strains

    August 3, 2026

    Trump cancels Iran strikes pending rapid nuclear deal

    August 3, 2026
    © 2026 Mashreq Daily | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.